Background False cardiac troponin (cTn) elevations from non-cardiac causes are a major concern. We aimed to assess terminal renal failure as a possible non-cardiac cause of elevated high-sensitivity cTnT (hs-cTnT) concentrations using renal transplantation as an in vivo model of rapid restoration of renal function.

Methods We analysed consecutive patients with end-stage renal disease (ESRD) undergoing renal transplantation at a single centre. Patients with perioperative myocardial infarction or injury were excluded. Changes in hs-cTnT and creatinine were measured pretransplant and at four post-transplant intervals (day 1, days 2–5 and days 14–180). A decrease of ≥25% in hs-cTnT within 24 hours post-transplant was deemed evidence of renal clearance recovery.

Results Among 45 patients (median age 67 years, 31% women), the median pretransplant plasma creatinine concentration was 608 μmol/L (IQR 482–830), and fell to 425 μmol/L (IQR 337–619) on day 1289 μmol/L (IQR 201–492) on days 2–5 and 126 μmol/L (IQR 103–191) on days 14–180 (p0.001, p0.001 and p=0.003, respectively). The median pretransplant hs-cTnT concentration was 48 ng/L (IQR 34–70). It fell to 26 ng/L (IQR 15–38; geometric mean of relative change 36%) on day 1 (p0.001) and then remained constant on days 2–5 (26 ng/L (IQR 18–35)) and days 14–180 (25 ng/L (IQR 20–30), p=ns).

A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard. This research, published in the July issue of The Journal of Nuclear Medicine, lays the foundation for further development of radionuclide therapies targeting CSCs, offering renewed hope for more effective treatment options and improved outcomes for patients.

CSCs are highly tumorigenic, self-renewable cells that play a key role in tumor relapse, metastasis, and therapy resistance. Although the clinical significance of eliminating CSCs is clearly recognized and CSC immunotherapies have been examined in preclinical and clinical evaluations, the development of such therapies remains a challenge.

“Radioimmunotherapy enables precise, target-specific delivery of particulate radiation to cancer-associated antigens, while minimizing off-target accumulation and increasing tumor retention and irradiation, which makes it a promising choice for targeting CSCs,” stated Jürgen Grünberg, Ph.D., senior scientist at the Center for Radiopharmaceutical Sciences, Center for Life Sciences at the Paul Scherrer Institute in Villigen, Switzerland.

Researchers have discovered a protein which is critical for steering melanoma cancer cells as they spread throughout the body. The malignant cells become dependent on this protein to migrate, pointing to new strategies for impeding metastasis.

The protein eIF2A is generally thought to spring into action when a cell is under stress, helping ribosomes launch protein synthesis. But according to a study published in the journal Science Advances, eIF2A has a completely different role in melanoma, helping cancerous cells control movement.

“Malignant cells that metastasize need to make their way through tissues in order to invade proximal or distant organs. Targeting eIF2A could be a new strategy to impede melanoma breaking free and seeding tumors elsewhere,” says Dr. Fátima Gebauer, corresponding author of the study and researcher at the Center for Genomic Regulation (CRG) in Barcelona.

The US Food and Drug Administration has approved a pill-sized device for treating rheumatoid arthritis, marking the first time the therapy has been approved for an autoimmune condition

A group of Australian scientists has uncovered a new way to fight some of the toughest cancers by targeting an overlooked cellular process called minor splicing. This tiny but vital mechanism turns out to be essential for the growth of certain tumors, especially those driven by KRAS mutations — a common but hard-to-treat culprit in cancer. By blocking minor splicing, researchers triggered DNA damage and activated the body’s own cancer-defense system, killing cancer cells while sparing healthy ones. The results in animal and human cell models are so promising that drug development is now underway, potentially paving the way for more effective and less toxic treatments across multiple cancer types.